We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves New Formulation for Otsuka & Lundbeck’s Abilify Maintena
FDA Approves New Formulation for Otsuka & Lundbeck’s Abilify Maintena
The FDA has signed off on a new formulation of Otsuka and Lundbeck’s collaborative anti-psychotic Abilify Maintena to be delivered via pre-filled dual chamber syringe.